In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First AMPA antagonist from Eisai's grows treatment options for refractory epilepsy

This article was originally published in Scrip

Executive Summary

Perampanel has become the first AMPA receptor antagonist to gain approval for the adjunctive treatment of partial-onset seizures. Despite underwhelming clinical trial data and relatively late market entry, perampanel's novel class, convenient dosing regimen, and preferable side-effect profile will support its uptake in the refractory patient population.

You may also be interested in...



Novartis: Gilenya gets back on track with NICE approval

Safety concerns and high price points have previously limited use of Novartis’s Gilenya (fingolimod) in the European multiple sclerosis market since its launch in January 2011. However, the decision by the UK's NICE to recommend Gilenya for active relapsing-remitting multiple sclerosis will support the product's future sales which are estimated to reach $2.2 billion across the seven major markets by 2020.

Sanofi: Aubagio's tolerability profile is key differentiator in light of lacklustre efficacy

The recent Phase III results from the TENERE study of Sanofi 's Aubagio (teriflunomide) comparing it with Rebif (interferon beta-1a; Merck Serono) in patients with relapsing forms of multiple sclerosis suggest that the once-daily oral drug's tolerability profile may prove to be its saving grace, say analysts at Datamonitor.

Attention all areas: non-ADHD indications offer growth potential for Shire’s Vyvanse

Positive top-line results from the first European Phase III study of Shire’s Vyvanse in children and adolescents with attention deficit hyperactivity disorder (ADHD) is likely to support the product's EU approval. However, given the competition in ADHD from Johnson & Johnson’s well-established Concerta, and the lower drug treatment rates for ADHD in Europe, the growth potential for Vyvanse may lie in the extension of indications beyond ADHD.

Topics

Related Companies

UsernamePublicRestriction

Register

SC018347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel